Recent studies revealed that ARID1A-deficient tumors are sensitive to PARP inhibitors and ATR inhibitors, and the combination of PARP inhibitors and ionizing radiation in the treatment of tumor cells with ARID1A deficiency has a selective and high efficiency (86, 134). The gene discussed is ATR; the disease is neoplasm.